We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · November 21, 2019

Elexacaftor + Tezacaftor + Ivacaftor Combination in Cystic Fibrosis Homozygous for the F508del Mutation

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Efficacy and Safety of the Elexacaftor Plus Tezacaftor Plus Ivacaftor Combination Regimen in People With Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial
Lancet 2019 Oct 30;[EPub Ahead of Print], HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, E Tullis, MA Mall, JJ Welter, BW Ramsey, CM McKee, G Marigowda, SM Moskowitz, D Waltz, PR Sosnay, C Simard, N Ahluwalia, F Xuan, Y Zhang, JL Taylor-Cousar, KS McCoy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading